GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory MeetingMarket Beat·Aug 14 at 02:04 AMGRAL+3.66%
FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Testbenzinga_article·Aug 10 at 12:30 PMGRAL+3.66%
Illumina sets Delaware court hearing on proposed dismissal of Icahn lawsuitPUBT·Aug 7 at 03:27 PMILMN+1.27%GRAL+3.66%
GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test | GRAL Stock NewsStockTitan·Aug 7 at 02:05 AMGRAL+3.66%
GRAIL | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 44.69 MEarnings Watch·Aug 5 at 10:09 PMGRAL+3.66%
GRAL: Q2 2026 delivered strong revenue growth and clinical milestones, with FDA approval anticipated in 2027Quartr·Aug 5 at 05:30 PMGRAL+3.66%
GRAIL Reports Second Quarter 2026 Financial Results | GRAL Stock NewsStockTitan·Aug 5 at 07:02 AMGRAL+3.66%
05:35 ETGRAL DEADLINE TODAY: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuitprnewswire·Aug 4 at 04:36 AMGRAL+3.66%
02:56 ETGRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit with SBS Lawprnewswire·Aug 3 at 01:56 AMGRAL+3.66%
08:43 ETGRAL Deadline: GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuitprnewswire·Aug 2 at 07:43 AMGRAL+3.66%
14:46 ETHAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 4, 2026 Lead Plaintiff Deadlineprnewswire·Jul 31 at 01:46 PMGRAL+3.66%
16:01 ETGRAIL to Present at the Canaccord Genuity 46th Annual Growth Conferenceprnewswire·Jul 30 at 03:01 PMGRAL+3.66%
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 4, 2026 in Grail, Inc. Lawsuit - GRALPR Newswire·Jul 30 at 09:07 AMGRAL+3.66%
